MiR-449c targets c-Myc and inhibits NSCLC cell progression (Q39178996)

https://doi.org/10.1002/1873-3468.14351

9 September 2017

1 reference

29 December 2023

title

MiR-449c targets c-Myc and inhibits NSCLC cell progression (English)

1 reference

non-small-cell lung carcinoma

9 September 2017

main subject

1 reference

Li-Jun Miao

1

1 reference

9 September 2017

Shi-Fu Huang

2

1 reference

9 September 2017

Zhen-Tao Sun

3

1 reference

9 September 2017

Zeng-Yan Gao

4

1 reference

9 September 2017

Rui-Xia Zhang

5

1 reference

9 September 2017

Ying Liu

6

1 reference

9 September 2017

Jing Wang

7

1 reference

9 September 2017

language of work or name

English

0 references

publication date

15 March 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

587

1 reference

9 September 2017

issue

9

1 reference

9 September 2017

page(s)

1359-1365

1 reference

A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

c-Myc as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

Expression of caspase-3 and c-myc in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

p53 represses c-Myc through induction of the tumor suppressor miR-145

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

MicroRNA function: multiple mechanisms for a tiny RNA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

MicroRNAs, macrocontrol: regulation of miRNA processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-21: an oncomir on strike in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-21 plays a pivotal role in gastric cancer pathogenesis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

miR-449 inhibits cell proliferation and is down-regulated in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2013.03.006

Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.FEBSLET.2013.03.006

Identifiers

DOI

10.1016/J.FEBSLET.2013.03.006

1 reference

9 September 2017

1 reference